Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye

Trial Profile

Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs AGN 232411 (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions
  • Sponsors Allergan
  • Most Recent Events

    • 13 Jul 2016 Status changed from recruiting to completed.
    • 06 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 23 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top